Coherus Oncology (CHRS) Return on Sales Growth (5y) (2019 - 2026)

Coherus Oncology (CHRS) Return on Sales Growth (5y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Coherus Oncology 195.05 Mn 28.00 Mn 8.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.00
Dec 31, 2025 1.00
Sep 30, 2025 1.00
Jun 30, 2025 33.00
Mar 31, 2025 -2.00
Dec 31, 2024 -1.00
Sep 30, 2024 6.00
Jun 30, 2024 4.00
Mar 31, 2024 75.00
Mar 31, 2023 160.00
Dec 31, 2022 169.00
Sep 30, 2022 120.00
Jun 30, 2022 47.00
Mar 31, 2022 515.00
Dec 31, 2021 89.00
Sep 30, 2021 -1.00
Jun 30, 2021 4.00
Mar 31, 2021 3.00
Dec 31, 2020 5.00
Sep 30, 2020 10.00